Constant Parameters:

embedding model: BAAI/bge-small-en-v1.5

chunk size: 256 overlap: 25 top k: 5

max new tokens: 190

re-ranking: 0 top n: 0

Queries:

How is the evidence on treatment of infections caused by 3GCephRE organized?

What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?

What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?

What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?

Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?

What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?

What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?

What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?

What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?

What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?

Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?

What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?

What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?

What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?

What is the comprehensive approach required to reduce surgical site infections (SSIs)?

What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?















